Find a Clinical Trial by Phase

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Back to Phases

Phase: II

38 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Doctor	Protocol No.	Title
Chiu, Vi K.	DEK-DKK1-P205	DEK-DKK1-P205: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish) (IRB#782)
Chung, Alice	IIT2015-06-CHUNG-SNBO	Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Clinical T1-2 Estrogen-Positive Breast Cancer Over Age 65 (IRB#41396)
Faries, Mark	MRNA-4157-P201	MRNA-4157-P201: A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (IRB#57650)
Figlin, Robert	PT2977-201	PT2977-201: A Phase 2 Trial of PT2977 In Combination With Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (IRB#54237)
Freedland, Stephen	IIT2018-06-FREEDLAND-AS3	IIT2018-06-FREEDLAND-AS3 (CAPS3): Carbohydrate and Prostate Study 3: Carbohydrate restricted diet intervention for men on prostate cancer active surveillance (IRB#53710)
Freedland, Stephen	IIT2018-23-FREEDLAND-POWR	IIT2018-23-Freedland-POWR: WALNUTS for POWER: Polyphenols, Omega-3 fatty acids, Weight loss, and EneRgy (IRB#55792)
Gong, Jun	ACCRU-GI-1617-SGNTUC-017	ACCRU-GI-1617-SGNTUC-017/MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (IRB#492)
Goodman, Marc	IIT2016-14-GOODMAN-NWUHCC	Statin Therapy to Reduce Disease Progression from Liver Cirrhosis to Cancer (IRB#47043)
Gupta, Amit	A031701	A031701: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations, (IRB#839)
Hamid, Omid	CLXH254C12201	CLXH254C12201: A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma (IRB#0975)
Hamid, Omid	EIIT2020-HAMID-S19-00008	S19-00008: A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma (IRB #390)
Hamid, Omid	GO40558	GO40558: A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma (IRB#54796)
Hamid, Omid	TAPUR	Targeted Agent and Profiling Utilization Registry (TAPUR) Study (IRB#49119)
Hendifar, Andrew	MK-3475-158	MK-3475-158-00: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) (IRB#43687)
Hendifar, Andrew	MK-7339-002	MK7339-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (IRB#57241)
Hendifar, Andrew	MK-7902-005	MK-7902-005: A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (IRB#0057697)
Jordan, Stanley	CLAZACOVID19	A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL-6 monoclonal) compared to placebo for the treatment of COVID-19 infection
Kulber, David	2019-SCAR-01	A Phase 2b/3 Randomized, Prospective, Double-Blind, Within-Subject Vehicle Controlled, Multi-Center Study to Determine the Efficacy and Safety of Granexin® Gel (100 uM and 200 uM concentration) in Reducing Scar Formation in Surgical Wounds following Bilateral Anchor Incision Breast Surgery
Lo, Simon	NANOPAC-2016-05	NANOPAC-2016-05: Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects with Locally Advanced Pancreatic Adenocarcinoma (IRB#49989)
Majlessipour, Fataneh	APEC1621B	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations (IRB#57477)
Majlessipour, Fataneh	APEC1621MASTER-APEC1621SC	APEC1621MASTER-APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master and Screening Protocol (IRB#57413)
McArthur, Heather	EIIT2020-MCARTHUR-TDM1	EIIT2020-McArthur-TDM1: A randomized phase II study to evaluate efficacy of T-DM1 with or without Palbociclib in the treatment of patients with metastatic HER2 positive breast cancer (IRB#132)
McArthur, Heather	IIT2018-01-MCARTHUR-IPI	IIT2018-01-McArthur-IPI: A Randomized Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation Versus Standard Peri-Operative Care in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer (IRB#52157)
McArthur, Heather	IIT2018-04-MCARTHUR-NEOHP	IIT2018-04-MCARTHUR-NEOHP: Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab (IRB#53566)
Mita, Alain	EAY131	EAY131: Molecular Analysis for Therapy Choice (MATCH) (IRB#41419)
Mita, Alain	P1719-SUR-Z11	P1719-SUR-Z11: A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours. (IRB#57155)
Moser, Franklin	20241	20241: Multicenter, single-blind, adaptive dose finding study of single intravenous injections of BAY 1747846 with corresponding blinded read in adult participants with known or highly suspected CNS lesions referred for contrast-enhanced MRI of the CNS (IRB#430)
Natale, Ronald	D6186C00001	D6186C00001:A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD) (IRB#97)
Noureddin, Mazen	VK2809-202	VK2809 A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VK2809 ADMINISTERED FOR 52 WEEKS FOLLOWED BY A 4-WEEK OFF-DRUG PHASE IN SUBJECTS WITH BIOPSY PROVEN NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS
Rokhsar, Sepehr	ME-401-003	ME-401-003: A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies (IRB#509)
Rudnick, Jeremy	17C0034-BTTC	17C0034-BTTC: A randomized, double blind phase II trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in newly diagnosed Glioblastoma (GBM) (IRB#00009)
Sandler, Howard	RTOG-3506	RTOG-3506: (STEEL) A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features (IRB#220)
Shiao, Stephen	IIT2017-07-HO-PEMBRORT	IIT2017-07-HO-PEMBRORT: Pilot Study of the Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients with Operable Breast Cancer (IRB#49440)
Tapson, Victor	20-0006	A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Wentzel, Kristopher	8951-CL-0103	A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression. (IRB#52384)
Yang, Ju Dong	IIT2020-01-YANG-G1001	IIT2020-01-YANG-G1001:Case-Control Study of the Glycotest HCC Panel vs AFP for the Detection of Early-Stage Hepatocellular Carcinoma (IRB#399)
Zumsteg, Zachary	NRG-HN004	NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin (IRB#46)
Zumsteg, Zachary	NRG-HN005	NRG-HN005: A RANDOMIZED PHASE II/III TRIAL OF DE-INTENSIFIED RADIATION THERAPY FOR PATIENTS WITH EARLY-STAGE, P16-POSITIVE, NON-SMOKING ASSOCIATED OROPHARYNGEAL CANCER (IRB#189)